Wed, April 20, 2022
Tue, April 19, 2022
Mon, April 18, 2022
Sun, April 17, 2022
Thu, April 14, 2022
Wed, April 13, 2022
Tue, April 12, 2022

Gena Wang Downgraded (BCRX) to Hold and Decreased Target to $13 on, Apr 18th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. and-decreased-target-to-13-on-apr-18th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Gena Wang of Barclays, Downgraded "BioCryst Pharmaceuticals, Inc." (BCRX) to Hold and Decreased Target from $22 to $13 on, Apr 18th, 2022.

Gena has made no other calls on BCRX in the last 4 months.



There are 3 other peers that have a rating on BCRX. Out of the 3 peers that are also analyzing BCRX, 2 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $14 on, Tuesday, April 12th, 2022
  • Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold and Held Target at $14 on, Monday, April 11th, 2022


This is the rating of the analyst that currently disagrees with Gena


  • Justin Kim of "Oppenheimer" Maintained at Buy with Decreased Target to $16 on, Monday, April 11th, 2022

Publication Contributing Sources